GB201714430D0 - Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue - Google Patents

Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue

Info

Publication number
GB201714430D0
GB201714430D0 GBGB1714430.4A GB201714430A GB201714430D0 GB 201714430 D0 GB201714430 D0 GB 201714430D0 GB 201714430 A GB201714430 A GB 201714430A GB 201714430 D0 GB201714430 D0 GB 201714430D0
Authority
GB
United Kingdom
Prior art keywords
modulation
tissue
expression
compositions
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1714430.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micol Romain
Original Assignee
Micol Romain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micol Romain filed Critical Micol Romain
Priority to GBGB1714430.4A priority Critical patent/GB201714430D0/en
Publication of GB201714430D0 publication Critical patent/GB201714430D0/en
Priority to MX2020002568A priority patent/MX2020002568A/es
Priority to PCT/US2018/049772 priority patent/WO2019051100A1/en
Priority to PL18792572.2T priority patent/PL3678673T3/pl
Priority to PT187925722T priority patent/PT3678673T/pt
Priority to AU2018328289A priority patent/AU2018328289B2/en
Priority to KR1020207009937A priority patent/KR102741572B1/ko
Priority to JP2020536493A priority patent/JP2020533411A/ja
Priority to EP23153161.7A priority patent/EP4218770A3/en
Priority to EP18792572.2A priority patent/EP3678673B1/en
Priority to CA3074293A priority patent/CA3074293A1/en
Priority to ES18792572T priority patent/ES2942890T3/es
Priority to RU2020112990A priority patent/RU2020112990A/ru
Priority to CN201880066146.2A priority patent/CN111212650A/zh
Priority to MX2020008606A priority patent/MX2020008606A/es
Priority to RU2020130763A priority patent/RU2803294C2/ru
Priority to US16/811,504 priority patent/US11359212B2/en
Priority to US17/706,522 priority patent/US12195746B2/en
Priority to JP2023127023A priority patent/JP2023159160A/ja
Priority to JP2024015220A priority patent/JP2024059656A/ja
Priority to JP2024080380A priority patent/JP2024122983A/ja
Priority to US18/984,898 priority patent/US20250129383A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1714430.4A 2017-09-07 2017-09-07 Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue Ceased GB201714430D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1714430.4A GB201714430D0 (en) 2017-09-07 2017-09-07 Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
CN201880066146.2A CN111212650A (zh) 2017-09-07 2018-09-06 用于编码核糖核酸在组织中的靶向递送、表达和调节的组合物和方法
CA3074293A CA3074293A1 (en) 2017-09-07 2018-09-06 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
RU2020112990A RU2020112990A (ru) 2017-09-07 2018-09-06 Композиции и процессы для направленной доставки, экспрессии и модуляции кодирующих рибонуклеиновых кислот в ткани
PL18792572.2T PL3678673T3 (pl) 2017-09-07 2018-09-06 Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach
PT187925722T PT3678673T (pt) 2017-09-07 2018-09-06 Composições e processos para aministração dirigida, expressão e modulação de ácidos robonucleicos codificantes num tecido
AU2018328289A AU2018328289B2 (en) 2017-09-07 2018-09-06 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
KR1020207009937A KR102741572B1 (ko) 2017-09-07 2018-09-06 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법
JP2020536493A JP2020533411A (ja) 2017-09-07 2018-09-06 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
EP23153161.7A EP4218770A3 (en) 2017-09-07 2018-09-06 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
EP18792572.2A EP3678673B1 (en) 2017-09-07 2018-09-06 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
MX2020002568A MX2020002568A (es) 2017-09-07 2018-09-06 Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido.
ES18792572T ES2942890T3 (es) 2017-09-07 2018-09-06 Composiciones y procedimientos para suministro, expresión y modulación dirigidos de ácidos ribonucleicos codificantes en tejidos
PCT/US2018/049772 WO2019051100A1 (en) 2017-09-07 2018-09-06 COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE
RU2020130763A RU2803294C2 (ru) 2018-02-19 2019-02-19 Композиции и способы органно-защитной экспрессии и модуляции кодирующих рибонуклеиновых кислот
MX2020008606A MX2020008606A (es) 2017-09-07 2019-02-19 Composiciones y metodos para la expresion y modulacion de proteccion de organos de acidos ribonucleicos codificadores.
US16/811,504 US11359212B2 (en) 2017-09-07 2020-03-06 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
US17/706,522 US12195746B2 (en) 2017-09-07 2022-03-28 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
JP2023127023A JP2023159160A (ja) 2017-09-07 2023-08-03 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
JP2024015220A JP2024059656A (ja) 2017-09-07 2024-02-02 コード化リボ核酸の器官保護発現および調節のための組成物および方法
JP2024080380A JP2024122983A (ja) 2017-09-07 2024-05-16 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
US18/984,898 US20250129383A1 (en) 2017-09-07 2024-12-17 Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1714430.4A GB201714430D0 (en) 2017-09-07 2017-09-07 Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue

Publications (1)

Publication Number Publication Date
GB201714430D0 true GB201714430D0 (en) 2017-10-25

Family

ID=60117350

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1714430.4A Ceased GB201714430D0 (en) 2017-09-07 2017-09-07 Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue

Country Status (14)

Country Link
US (3) US11359212B2 (https=)
EP (2) EP4218770A3 (https=)
JP (4) JP2020533411A (https=)
KR (1) KR102741572B1 (https=)
CN (1) CN111212650A (https=)
AU (1) AU2018328289B2 (https=)
CA (1) CA3074293A1 (https=)
ES (1) ES2942890T3 (https=)
GB (1) GB201714430D0 (https=)
MX (2) MX2020002568A (https=)
PL (1) PL3678673T3 (https=)
PT (1) PT3678673T (https=)
RU (1) RU2020112990A (https=)
WO (1) WO2019051100A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
JP7539723B2 (ja) 2020-02-21 2024-08-26 コンバインド セラピューティクス インコーポレイテッド コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法
MX2023001187A (es) 2020-07-31 2023-04-04 Combined Therapeutics Inc Composiciones y métodos para una vacunación mejorada.
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
CN113444744A (zh) * 2021-06-28 2021-09-28 北京鼎成肽源生物技术有限公司 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用
CN114107347B (zh) * 2021-11-24 2022-10-28 中国人民解放军空军军医大学 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421576A1 (en) * 2000-09-15 2002-03-28 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EP2213300B1 (en) * 2001-05-09 2015-03-25 Takara Bio, Inc. Composition and method for treating cancer using herpes virus
ATE420160T1 (de) * 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
JPWO2011101912A1 (ja) * 2010-02-19 2013-06-17 国立大学法人 東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
DE19216461T1 (de) * 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2014337156A1 (en) * 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
BR112016009465A8 (pt) * 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
CN120242030A (zh) * 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
CA2955375A1 (en) * 2014-07-17 2016-01-21 Modernatx, Inc. Terminal modifications of polynucleotides
US11351271B2 (en) * 2014-09-08 2022-06-07 Massachusetts Institute Of Technology RNA-based logic circuits with RNA binding proteins, aptamers and small molecules
EP3663403A1 (en) * 2014-09-26 2020-06-10 University of Massachusetts Rna-modulating agents
EP3233132A4 (en) * 2014-12-19 2018-06-27 Modernatx, Inc. Terminal modifications of polynucleotides
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
EP3359670B2 (en) * 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CN108474003A (zh) * 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
KR20180136435A (ko) * 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
CN110402145A (zh) 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP4008333A1 (en) 2018-02-19 2022-06-08 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP7539723B2 (ja) * 2020-02-21 2024-08-26 コンバインド セラピューティクス インコーポレイテッド コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法

Also Published As

Publication number Publication date
JP2024059656A (ja) 2024-05-01
US12195746B2 (en) 2025-01-14
AU2018328289B2 (en) 2025-07-10
MX2020008606A (es) 2020-09-21
JP2020533411A (ja) 2020-11-19
EP3678673B1 (en) 2023-01-25
RU2020112990A (ru) 2021-10-07
RU2020130763A3 (https=) 2022-03-22
US20250129383A1 (en) 2025-04-24
CN111212650A (zh) 2020-05-29
EP4218770A3 (en) 2023-08-09
US20200255863A1 (en) 2020-08-13
WO2019051100A1 (en) 2019-03-14
RU2020130763A (ru) 2022-03-21
RU2020112990A3 (https=) 2022-03-05
ES2942890T3 (es) 2023-06-07
KR20200104282A (ko) 2020-09-03
AU2018328289A1 (en) 2020-03-19
JP2023159160A (ja) 2023-10-31
PL3678673T3 (pl) 2023-07-10
CA3074293A1 (en) 2019-03-14
US11359212B2 (en) 2022-06-14
PT3678673T (pt) 2023-04-24
KR102741572B1 (ko) 2024-12-10
EP4218770A2 (en) 2023-08-02
US20220220506A1 (en) 2022-07-14
JP2024122983A (ja) 2024-09-10
EP3678673A1 (en) 2020-07-15
MX2020002568A (es) 2020-09-18

Similar Documents

Publication Publication Date Title
GB201714430D0 (en) Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
IL287749A (en) Compositions for administering implantable drugs and methods of their use
SMT202200358T1 (it) Composizioni e metodi di rilascio degli agenti terapeutici
IL268999B (en) Compounds and preparations for intracellular administration of medicinal agents
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
SG11202004680UA (en) Cellular compositions and methods of treatment i
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL269901B (en) Pharmaceutical compounds and methods of treating cardiovascular diseases
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
EP3265165A4 (en) Implant applicators and methods of administering implants
IL257670A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
IL271596A (en) Preparations for administering drugs and methods of using them
IL254625A0 (en) Device for targeted delivery of a therapeutic implant
IL272036A (en) Methods and compositions for treating pain using capsaicin
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
IL271327A (en) Compositions and methods for enhancing hyperthermic therapy
PL3294279T3 (pl) Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3171858A4 (en) Method and composition for targeted delivery of therapeutic agents
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL271211B1 (en) Acetyl leucine for use in the treatment of migraine
IL255168A0 (en) Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer
EP3148468B8 (en) Apparatus for stimulation and/or treatment of anatomical tissues

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)